Pathophysiology of severe asthma - PubMed (original) (raw)
Review
. 2000 Dec;106(6):1033-42.
doi: 10.1067/mai.2000.111307.
Affiliations
- PMID: 11112883
- DOI: 10.1067/mai.2000.111307
Review
Pathophysiology of severe asthma
W W Busse et al. J Allergy Clin Immunol. 2000 Dec.
Abstract
Although asthma affects nearly 8% of the adult population, most of these patients have mild-to-moderate disease that can be controlled with appropriate treatment. It is estimated, however, that 5% to 10% of patients with asthma have severe disease that is unresponsive to typical therapeutics, including corticosteroids. Because patients with severe asthma are disproportionately affected by their disease, in terms of both impaired lifestyle and health care costs, the National Heart, Lung, and Blood Institute sponsored a workshop on the pathogenesis of severe asthma. The goals of this workshop were to begin to define the characteristics of severe asthma. In these discussions, it was clear that many characteristics need to be considered in defining this phenotype of asthma, including symptoms, intensity of therapy (including administration of systemic corticosteroids), and impairment of lung function. Also discussed were potential mechanisms of severe asthma including the role of allergic diseases, which may play less of a role in severe asthma than in mild-to-moderate disease, and infections. A major limitation to control of severe asthma is the recalcitrant response of these patients to usual therapy including systemic corticosteroids; the potential of other therapies was reviewed. From these discussions, recommendations were made for future research needs to gain insights into a difficult therapeutic and possibly novel mechanistic area of asthma.
Similar articles
- Severe asthma: lessons from the Severe Asthma Research Program.
Wenzel SE, Busse WW; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Wenzel SE, et al. J Allergy Clin Immunol. 2007 Jan;119(1):14-21; quiz 22-3. doi: 10.1016/j.jaci.2006.10.025. J Allergy Clin Immunol. 2007. PMID: 17208583 Review. - Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire.
Gaga M, Papageorgiou N, Yiourgioti G, Karydi P, Liapikou A, Bitsakou H, Zervas E, Koulouris NG, Holgate ST; ENFUMOSA Study Group. Gaga M, et al. Clin Exp Allergy. 2005 Jul;35(7):954-9. doi: 10.1111/j.1365-2222.2005.02281.x. Clin Exp Allergy. 2005. PMID: 16008684 - Therapeutic targets for new therapy for corticosteroid refractory asthma.
Ito K, Mercado N. Ito K, et al. Expert Opin Ther Targets. 2009 Sep;13(9):1053-67. doi: 10.1517/14728220903078431. Expert Opin Ther Targets. 2009. PMID: 19659447 Review. - A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items.
Valero A, Ferrer M, Sastre J, Navarro AM, Monclús L, Martí-Guadaño E, Herdman M, Dávila I, Del Cuvillo A, Colás C, Baró E, Antépara I, Alonso J, Mullol J. Valero A, et al. J Allergy Clin Immunol. 2007 Aug;120(2):359-65. doi: 10.1016/j.jaci.2007.04.006. Epub 2007 May 25. J Allergy Clin Immunol. 2007. PMID: 17531304 - Impact of 'mild' asthma on health outcomes: findings of a systematic search of the literature.
Chapman KR. Chapman KR. Respir Med. 2005 Nov;99(11):1350-62. doi: 10.1016/j.rmed.2005.03.020. Epub 2005 Apr 26. Respir Med. 2005. PMID: 16210094 Review.
Cited by
- Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational RESONANCE study in France.
Roche N, Garcia G, de Larrard A, Cancalon C, Bénard S, Perez V, Mahieu A, Vieu L, Demoly P. Roche N, et al. BMJ Open. 2022 Aug 24;12(8):e060160. doi: 10.1136/bmjopen-2021-060160. BMJ Open. 2022. PMID: 36002203 Free PMC article. - Evaluation of Rapid Onset of Action of ICS/LABA Combination Therapies on Respiratory Function in Asthma Patients: A Single-Center, Open-Label, Randomized, Crossover Trial.
Ohbayashi H, Kudo S, Ariga M. Ohbayashi H, et al. Pulm Ther. 2018 Dec;4(2):159-169. doi: 10.1007/s41030-018-0062-x. Epub 2018 Sep 7. Pulm Ther. 2018. PMID: 32026393 Free PMC article. - Ultrastructural changes of airway in murine models of allergy and diet-induced metabolic syndrome.
Leishangthem GD, Mabalirajan U, Singh VP, Agrawal A, Ghosh B, Dinda AK. Leishangthem GD, et al. ISRN Allergy. 2013 Sep 10;2013:261297. doi: 10.1155/2013/261297. eCollection 2013. ISRN Allergy. 2013. PMID: 24106613 Free PMC article. - Comparison of doses of Nebulized Magnesium sulphate as an adjuvant treatment with salbutamol in children with Status Asthmaticus.
Asif R, Rais H, Bai P, Aziz R. Asif R, et al. Pak J Med Sci. 2024 May-Jun;40(5):927-932. doi: 10.12669/pjms.40.5.7682. Pak J Med Sci. 2024. PMID: 38827880 Free PMC article. - On the Role of Mechanics in Chronic Lung Disease.
Eskandari M, Pfaller MR, Kuhl E. Eskandari M, et al. Materials (Basel). 2013 Dec 4;6(12):5639-5658. doi: 10.3390/ma6125639. Materials (Basel). 2013. PMID: 28788414 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical